The first patient has been dosed, and the observation period completed, in a clinical trial in China that’s testing iRegene Therapeutics’ NouvNeu001 cell therapy for moderate to advanced Parkinson’s disease. The Phase 1/2 clinical trial (NCT06167681) started in early January at Beijing Hospital, following a green light from the…
Vaxxinity has entered into a research collaboration with the University of Florida to advance the development of vaccines for neurodegenerative diseases, including Parkinson’s disease. Funded by a grant from the state of Florida, the partnership aims to advance Vaxxinity’s lead immunotherapy candidates, designed to prevent and manage…
Knight Therapeutics has entered into an exclusive license agreement with Amneal Pharmaceuticals giving it rights to apply for regulatory approval of IPX203 in Canada and across Latin America, and, if granted, to market the Parkinson’s disease treatment there. IPX203 is an investigational, extended-release oral formulation…
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded an $873,000 grant to Vesper Bio to advance the preclinical development of small-molecule therapies aiming to increase progranulin levels in people with Parkinson’s disease. Low levels of progranulin, a protein critical for immune activity and…
Centogene and The Michael J. Fox Foundation (MJFF) are teaming up on a research project to investigate genetic risk factors for Parkinson’s disease, with a particular focus on GBA gene mutations. This project’s main goal is to better understand how certain variations in the GBA gene are connected…
A new brain imaging method may help diagnose mild traumatic brain injury (mTBI), which according to some studies can be associated with a 50% higher risk of developing Parkinson’s. Available methods, like magnetic resonance imaging (MRI), leave most cases of mTBI, or concussions, undiagnosed. They occur when a physical…
Monitoring symptoms at home using smartwatch-smartphone technology collected individual profiles of tremor and activity fluctuations among people with advanced Parkinson’s disease being treated with levodopa. The technology can provide useful information to improve treatments and patient outcomes and, by combining it with telemedicine and other digital health tools, could…
Treatment with AB-1005 (AAV2-GDNF), AskBio’s investigational gene therapy, was safe and well tolerated among patients with mild to moderate Parkinson’s disease, according to top-line results from a Phase 1b clinical trial. The company, wholly owned by Bayer, has also completed an 18-month data collection which demonstrated the…
Targeted ocular spectroscopy, a technology that allows real-time imaging of the back of the eye (or eye fundus) while observing how light interacts with specific structures in the retina, can help diagnose several eye and neurological conditions, including Parkinson’s disease, according to a recent study. The retina is the…
Researchers have developed a three-dimensional brain organoid — a “mini-organ” model of the brain — that replicates a human neural network known as the “dopaminergic reward pathway” in structure and function. Despite the importance of the neurotransmitter dopamine in Parkinson’s disease, key mechanisms of this brain system are not…
Get regular updates to your inbox.